Stock NMRA NEUMORA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Market Closed - Nasdaq
Other stock markets
 20:59:50 29/05/2024 BST 		5-day change 1st Jan Change
9.5 USD -0.11% Intraday chart for Neumora Therapeutics, Inc. -1.55% -44.28%
05-14 Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression MT
05-14 Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression CI

Evolution of the average Target Price on Neumora Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d62b77b150ecc4fc295175f.Fpm29J9kuxn4HJ7flyVMdByhvU3b9XFA2WKJl3e7t0o.I6_1ma8q0CGiV9299W0bOkTm-X2BnUF2jC7I3SXXghlTtIKnxhz2cc5E_Q~c30310e53ab00b88a37b41dc1498b254

Analyst Recommendations on Neumora Therapeutics, Inc.

JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating MT
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk MT
Deutsche Bank Initiates Coverage on Neumora Therapeutics With Hold Rating, $13 Price Target MT
JPMorgan Initiates Neumora Therapeutics at Overweight Rating With $21 Price Target MT
BofA Securities Initiates Neumora Therapeutics at Buy Rating MT
RBC Initiates Neumora Therapeutics at Outperform, Speculative Risk With $24 Price Target Amid Bullish View on Lead Drug in Major Depressive Disorder MT
Guggenheim Starts Neumora Therapeutics at Buy With $22 Price Target MT
William Blair Starts Neumora Therapeutics With Outperform Rating MT
BofA Securities Starts Neumora Therapeutics With Buy Rating MT
Stifel Starts Neumora Therapeutics at Buy MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.51 USD
Average target price
23.84 USD
Spread / Average Target
+150.70%
High Price Target
29 USD
Spread / Highest target
+204.94%
Low Price Target
18 USD
Spread / Lowest Target
+89.27%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Neumora Therapeutics, Inc.

JPMorgan Chase
RBC Capital Markets
Deutsche Bank Securities
BofA Securities
Guggenheim
Stifel Nicolaus
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NMRA Stock
  4. Consensus Neumora Therapeutics, Inc.